“…However, if the concentration of NO or • O is reduced with the help of NO synthase inhibitors, NO traps (for example, diethyldithiocarbamate– disulfiram) and/or inhibitors of free radical processes involving NO or • O , then it is possible to influence almost all pathological processes occurring against the background of hypoxia/ischemia, inflammatory processes and the activation of immune/autoimmune processes. We have every reason to believe that the same processes and mechanisms develop when solving both problems associated with hemorrhagic and ischemic strokes [ 181 – 187 ], as well as problems of tissue engineering structures, which include the creation of a new center of local neurohumoral regulation based on the formation of new nervous and vascular connections [ 41 – 57 ]. Therefore, we hypothesize that using inhibitors of NO synthase, NO traps (such as diethyldithiocarbamate) and/or inhibitors of free radical processes involving NO or • O , makes it possible to reduce the number of deaths in those 5–30% of cases when the development of destructive changes is observed in the displaced ganglion.…”